research use only

BMS-927711 (Rimegepant) CGRP Receptor antagonist

Cat.No.S6659

Rimegepant (BMS-927711, BHV-3000) is a potent, selective, competitive human calcitonin gene-related peptide (CGRP) receptor antagonist with ki of 0.027 nM.
BMS-927711 (Rimegepant) CGRP Receptor antagonist Chemical Structure

Chemical Structure

Molecular Weight: 534.56

Jump to

Quality Control

Batch: Purity: 99.99%
99.99

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (187.06 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 3 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 534.56 Formula

C28H28F2N6O3

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1289023-67-1 -- Storage of Stock Solutions

Synonyms BHV-3000 Smiles C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6

Mechanism of Action

Targets/IC50/Ki
CGRP receptor
(Cell-free assay)
0.027 nM(Ki)
In vitro

Rimegepant (BMS-927711, BHV-3000) is a potent, selective, competitive human calcitonin gene-related peptide (CGRP) receptor antagonist with ki of 0.027 nM.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06409832 Recruiting
Migraine|Migraine With Aura|Migraine Without Aura|Chronic Migraine
University of Florence|IRCCS National Neurological Institute C. Mondino Foundation|Società italiana per lo studio delle Cefalee (SISC)|Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari|Università degli Studi dell''Aquila|University of Roma La Sapienza|Azienda Ospedaliero Universitaria Policlinico Modena|Ospedale di Piove di Sacco|Azienda Ospedaliero-Universitaria di Parma|Azienda Ospedaliera S. Maria della Misericordia|Azienda Ospedaliera Città della Salute e della Scienza di Torino|Cliniche Humanitas Gavazzeni|University of Campania Luigi Vanvitelli|Ospedale di Prato|Azienda Policlinico Umberto I|Auxologico San Luca Milano|ASST Spedali Civili Brescia|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
March 26 2024 --
NCT05888766 Not yet recruiting
Migraine Disorders
University of Roma La Sapienza
July 1 2023 --
NCT05518123 Recruiting
Migraine
Pfizer
November 7 2022 Phase 4
NCT05509400 Recruiting
Migraine
Pfizer
October 18 2022 Phase 4
NCT05399485 Active not recruiting
Migraine
Pfizer
August 9 2022 Phase 3
NCT05262517 Terminated
Temporomandibular Disorders (TMD)
Pfizer
May 5 2022 Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.